Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 1-7

  Moton, Allen ^a   Krishna, Gopal ^a   Ma, Lei ^a   O'Mara, Edward ^a   Prasad, Pratapa ^a   McLeod, James ^a   Preston, Richard A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Antifungal agents; Liver disease; Pharmacokinetics; Posaconazole; Safety

Indexed keywords

POSACONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; LIPID DIET; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; LIVER; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; TRIAZOLES;

EID: 77649201260     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903364657     Document Type: Article

References (29)

1. Keating GM. Posaconazole. Drugs 2005;65:1553-67 (Pubitemid 41124308)
2. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15 (Pubitemid 43807519)
3. Krishna G, Tarif MA, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008;28: 1223-32
4. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22
5. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95 (Pubitemid 37040249)
6. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9 (Pubitemid 43807517)
7. Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition December 3-7, 2006 Anaheim, CA, 2006
8. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36 (Pubitemid 350234311)
9. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495-502 (Pubitemid 46185266)
10. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50: 658-66 (Pubitemid 43190980)
11. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51:812-18 (Pubitemid 46355260)
12. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185-92 (Pubitemid 40490442)
13. Lipp HP. Antifungal agents -clinical pharmacokinetics and drug interactions. Mycoses 2008;51(Suppl 1):7-18
14. NOXAFIL (posaconazole) oral suspension [prescribing information]. Kenilworth, NJ: Schering Corporation, May 2008
15. Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66
16. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50:1881-3
17. Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther 2007;29:1862-86 (Pubitemid 350212806)
18. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51 (Pubitemid 39129357)
19. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm072123.pdf [Last accessed 30 June 2009]
20. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
21. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36 (Pubitemid 44856187)
22. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Available from http://ctep.cancer.gov/reporting/ctc-v30.html [Last accessed 13 November 2007]
23. Courtney R, Laughlin M, Gontz H, et al. Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease. Poster presented at: American Association of Pharmaceutical Scientists 2000 Annual Meeting and Exposition; October 29 to November 2, 2000, Indianapolis, IN
24. Saha P, Kou JH. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. Eur J Pharm Biopharm 2000;50:403-11
25. Diflucan (fluconazole tablets) (fluconazole injection -for intravenous infusion only) (fluconazole for oral suspension) [prescribing information]. New York, NY: Pfizer Inc, August 2004
26. Sporanox (itraconazole) capsules [prescribing information]. Titusville, NJ: Janssen, June 2006
27. Sporanox (itraconazole) oral solution [prescribing information]. Raritan, NJ: Ortho Biotech Products, L.P., January 2004
28. Sporanox (itraconazole) injection [prescribing information]. Raritan, NJ: Ortho Biotech Products, LP, April 2001
29. VFEND I.V. (voriconazole) for injection, VFEND tablets (voriconazole), VFEND (voriconazole) for oral suspension [prescribing information]. New York, NY: Pfizer Inc, March 2008